NCT00553787View on ClinicalTrials.gov

Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

PHASE3CompletedINTERVENTIONAL
Enrollment

2,487

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
ObesityType 2 Diabetes
Interventions
DRUG

VI-0521

phentermine 15 mg and topiramate 92 mg, po once daily

DRUG

VI-0521

phentermine 7.5 mg and topiramate 46 mg, po once daily

DRUG

VI-0521

placebo

Trial Locations (6)

10025

Research Site, New York

27710

Research Site, Durham

35294

Research Site, Birmingham

43623

Research Site, Toledo

78731

Research Site, Austin

06877

Research Site, Ridgefield

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

VIVUS LLC

INDUSTRY

NCT00553787 - Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions | Biotech Hunter | Biotech Hunter